ANTHEM BIOSCIENCES Q2 FY27 CONCALL: TARGETS DOUBLE-DIGIT FY27 REVENUE GROWTH, SUSTAINABLE ~43% EBITDA MARGIN, ₹1,200 CR UNIT 4 CAPEX & 1.5X ASSET TURNS; EXPECTS NEW MOLECULE COMMERCIALISATION & CAPACITY EXPANSION BY MARCH 2028